Evaluation of GDC-9545 Monotherapy and Combination Therapy with Palbociclib and/or LHRH Agonist in Locally Advanced or Metastatic ER-Positive Breast Cancer

The primary objective of this study is to evaluate the **safety**, **pharmacokinetics**, and activity of GDC-9545 when administered alone or in combination with Palbociclib and/or an LHRH agonist in patients with **locally advanced or metastatic estrogen receptor-positive breast cancer**. This is clinically relevant as it aims to determine the therapeutic potential and tolerability of GDC-9545, which could inform treatment strategies for this specific subtype of breast cancer. No secondary objectives are provided in the available data.

The clinical trial involves a total of **113 participants** diagnosed with **locally advanced or metastatic estrogen receptor-positive breast cancer**. The study population is exclusively female, with an age range that includes both adults and older adults. Participants were selected based on specific criteria, although the principal inclusion criteria are not provided. The trial does not include male subjects and involves a vulnerable population. Lifestyle considerations such as diet, physical activity, or habits are not specified in the available data. The selection process and any additional relevant criteria are not detailed by the sponsor.

The clinical trial is designed to evaluate the **safety**, pharmacokinetics, and activity of GDC-9545, either alone or in combination with Palbociclib and/or an LHRH agonist, in patients diagnosed with **locally advanced or metastatic estrogen receptor-positive breast cancer**. This study is structured as a Phase 3, randomized, double-blind, controlled trial, ensuring a robust methodology to assess the investigational treatment's efficacy and safety profile. The trial commenced recruitment on July 31, 2018, and is projected to conclude by June 30, 2025, encompassing a comprehensive duration to gather significant data.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Regular follow-up visits will be scheduled to monitor the participants' health status, treatment adherence, and any adverse events. These visits are critical for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of a participant's involvement, where final assessments will be conducted to evaluate the long-term effects of the treatment.

The expected length of participant involvement will vary depending on individual response and tolerance to the treatment, but it is anticipated to last until the study's end date unless specific conditions necessitate early termination. Such conditions may include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed appropriate by the study investigators. The trial's design and procedures are meticulously crafted to ensure the collection of high-quality data while prioritizing participant safety and adherence to ethical standards.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be described. The data does not include any information about the **disease** being studied, the trial's main objective, or the role of the product in the trial. Consequently, a comprehensive description of the treatments used in this clinical trial cannot be constructed based on the current dataset.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to conclude by June 30, 2025, with recruitment having commenced on July 31, 2018. The efficacy assessment will be conducted through a series of pre-determined endpoints, although specific parameters or endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the collection and analysis of efficacy data is consistent with clinical trial standards. The trial's design and execution will adhere to rigorous protocols to ensure the reliability and validity of the efficacy outcomes.